SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wesley H. Bronson, I. David Kaye, Kenneth A. Egol, Atypical Femur Fractures: A Review, Current Osteoporosis Reports, 2014, 12, 4, 446

    CrossRef

  2. 2
    Laura K. Bachrach, Diagnosis and treatment of pediatric osteoporosis, Current Opinion in Endocrinology & Diabetes and Obesity, 2014, 21, 6, 454

    CrossRef

  3. 3
    Pingal A. Desai, Parth A. Vyas, Joseph M. Lane, Atypical Femoral fractures: A Review of the Literature, Current Osteoporosis Reports, 2013, 11, 3, 179

    CrossRef

  4. 4
    Nicola Dalbeth, Bregina Pool, Angela Stewart, Anne Horne, Meaghan E. House, Jillian Cornish, Ian R. Reid, No Reduction in Circulating Preosteoclasts 18 Months after Treatment with Zoledronate: Analysis from a Randomized Placebo Controlled Trial, Calcified Tissue International, 2013, 92, 1, 1

    CrossRef

  5. 5
    Olga Di Fede, Vittorio Fusco, Domenica Matranga, Luigi Solazzo, Mario Gabriele, Giovanni M. Gaeta, Gianfranco Favia, Delia Sprini, Franco Peluso, Giuseppe Colella, Paolo Vescovi, Giuseppina Campisi, Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases, European Journal of Internal Medicine, 2013, 24, 8, 784

    CrossRef

  6. 6
    S. Bourke, M. J. Bolland, A. Grey, A. M. Horne, D. J. Wattie, S. Wong, G. D. Gamble, I. R Reid, The impact of dietary calcium intake and vitamin D status on the effects of zoledronate, Osteoporosis International, 2013, 24, 1, 349

    CrossRef

  7. 7
    J. Devine, S. Trice, Z. Finney, S. Yarger, E. Nwokeji, A. Linton, W. Davies, A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System, Osteoporosis International, 2012, 23, 4, 1415

    CrossRef

  8. You have free access to this content8
    Juliet E Compston, John P Bilezikian, Bisphosphonate therapy for osteoporosis: The long and short of it, Journal of Bone and Mineral Research, 2012, 27, 2
  9. 9
    Kim Naylor, Richard Eastell, Bone turnover markers: use in osteoporosis, Nature Reviews Rheumatology, 2012, 8, 7, 379

    CrossRef

  10. 10
    Maryam Iranikhah, Teresa W. Wilborn, Terri M. Wensel, Jodi B. Ferrell, Denosumab for the Prevention of Skeletal-Related Events in Patients with Bone Metastasis from Solid Tumor, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012, 32, 3
  11. 11
    Andrew Grey, Mark J. Bolland, Anne Horne, Diana Wattie, Meaghan House, Greg Gamble, Ian R. Reid, Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial, Bone, 2012, 50, 6, 1389

    CrossRef

  12. 12
    Steven Boonen, Serge Ferrari, Paul D Miller, Erik F Eriksen, Philip N Sambrook, Juliet Compston, Ian R Reid, Dirk Vanderschueren, Felicia Cosman, Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective, Journal of Bone and Mineral Research, 2012, 27, 5
  13. 13
    Matthew R. Allen, David B. Burr, Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know, Bone, 2011, 49, 1, 56

    CrossRef

  14. 14
    Ian R. Reid, Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies, Skeletal Radiology, 2011, 40, 9, 1191

    CrossRef

  15. 15
    R. Graham G. Russell, Bisphosphonates: The first 40years, Bone, 2011, 49, 1, 2

    CrossRef

  16. 16
    Ian R. Reid, Mark J. Bolland, Philip N. Sambrook, Andrew Grey, Calcium supplementation: Balancing the cardiovascular risks, Maturitas, 2011, 69, 4, 289

    CrossRef

  17. 17
    Andrew J. Laster, S. Bobo Tanner, Duration of Treatment in Postmenopausal Osteoporosis: How Long to Treat and What are the Consequences of Cessation of Treatment?, Rheumatic Disease Clinics of North America, 2011, 37, 3, 323

    CrossRef

  18. 18
    Matthew R Allen, Salvatore L Ruggiero, Osteonecrosis of the jaw: Recent clinical and preclinical advances, IBMS BoneKEy, 2011, 8, 3, 141

    CrossRef

  19. 19
    Stergios A. Polyzos, Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget’s disease of bone, Clinical Rheumatology, 2011, 30, 1, 149

    CrossRef

  20. 20
    P. Peris, M. Torra, V. Olivares, R. Reyes, A. Monegal, A. Martínez-Ferrer, N. Guañabens, Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover, Bone, 2011, 49, 4, 706

    CrossRef

  21. 21
    Matthew R. Allen, The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing, Odontology, 2011, 99, 1, 8

    CrossRef

  22. 22
    Serge Ferrari, Ego Seeman, David Karasik, David G Little, Toshio Matsumoto, Clinical and basic research papers – November 2010, IBMS BoneKEy, 2010, 7, 11, 373

    CrossRef